Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9747755 | 0.90 | ABCB11 (0.51) | — | |
| Water SCHEMBL11468777 | 0.89 | ABCB11 (0.50) | — | |
| SCHEMBL11223030 | 0.85 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL10905309 | 0.83 | GABRP (0.43) | — | |
| SCHEMBL9747865 | 0.82 | HPGD (0.46) | — | |
| SCHEMBL9747171 | 0.81 | ABCB11 (0.51) | — | |
| Nepafenac SCHEMBL93835 | 0.79 | ABCB11 (0.62) | — | |
| Nepafenac SCHEMBL29377340 | 0.79 | ABCB11 (0.62) | — | |
| SCHEMBL9747303 | 0.79 | ABCB11 (0.49) | — | |
| SCHEMBL23337438 | 0.79 | MAPT (0.55) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630909-B2 | Process for the preparation of nepafenac | MYLAN LABORATORIES LTD (IN) | 2017-04-25 | — | — | US | claimed |
| US-20160214927-A1 | Process for the preparation of nepafenac | MYLAN LABORATORIES LTD, (IN) | 2016-07-28 | — | — | US | claimed |
| EP-3013790-A1 | PROCESS FOR THE PREPARATION OF NEPAFENAC | Mylan Laboratories Ltd. (IN) | 2016-05-04 | — | — | EP | claimed |
| WO-2014207769-A1 | PROCESS FOR THE PREPARATION OF NEPAFENAC | MYLAN LABORATORIES LTD (IN) | 2014-12-31 | — | — | WO | claimed |
| CN-1088992-C | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 2002-08-14 | — | — | CN | claimed |
| EP-0716600-B1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LAB INC (US) | 2002-04-03 | — | — | EP | claimed |
| CN-1129397-A | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 1996-08-21 | — | — | CN | claimed |
| EP-0716600-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1995033457-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-5475034-A | Adminstering 3-benzoylphenylacetamide derivatives | ALCON LABORATORIES, INC. (US) | 1995-12-12 | — | — | US | claimed |
| US-4313949-A | Method of producing an inhibitory effect on blood platelet aggregation | A. H. ROBINS COMPANY, INC. (US) | 1982-02-02 | — | — | US | claimed |
| US-9630909-B2 | Process for the preparation of nepafenac | MYLAN LABORATORIES LTD (IN) | 2017-04-25 | — | — | US | disclosed |
| US-9630909-B2 | Process for the preparation of nepafenac | MYLAN LABORATORIES LTD (IN) | 2017-04-25 | — | — | US | disclosed |
| US-9630909-B2 | Process for the preparation of nepafenac | MYLAN LABORATORIES LTD (IN) | 2017-04-25 | — | — | US | disclosed |
| US-20160214927-A1 | Process for the preparation of nepafenac | MYLAN LABORATORIES LTD, (IN) | 2016-07-28 | — | — | US | disclosed |
| EP-0716600-B1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LAB INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0716600-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1995033457-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5475034-A | Adminstering 3-benzoylphenylacetamide derivatives | ALCON LABORATORIES, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-4313949-A | Method of producing an inhibitory effect on blood platelet aggregation | A. H. ROBINS COMPANY, INC. (US) | 1982-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214927-A1 | Process for the preparation of nepafenac | SCN2B, SCN3A, SCN2A | ALOX15 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.